Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma


CD16, the type III receptor for IgG, is expressed on neutrophils, natural killer cells, and some T lymphocytes, mast cells, and activated monocytes but not on cells of the B-lymphocyte lineage including plasma cells. It is also produced in a soluble form found in serum. We analyzed sera from 165 multiple-myeloma patients, 29 patients with monoclonal gammopathies of unknown significance, and 20 normal disease-free donors. We found that the level of soluble CD16 was significantly decreased in sera from patients with multiple myeloma compared to sera from healthy and monoclonal gammopathies of unknown significance donors (P=0.0001). In addition, a stage-dependent decrease in soluble CD16 was observed, with a highly significant difference (P=0.004) between stage I and stage II+III myeloma patients. The correlation between the myeloma stage and the serum level of soluble CD16, which is related to the host response, was found to be more sensitive than that of β2-microglobulin, which reflects the tumor burden. The concomitant evaluation of the serum levels of these two markers allows better staging and therefore has a more precise prognostic value.

This is a preview of subscription content, log in to check access.


  1. 1.

    Durie BGM, Salmon SS: A clinical staging system for multiple myeloma. Cancer 36:842–854, 1975

  2. 2.

    Durie BGM: Staging and kinetics of multiple myeloma. Semin Oncol 13:300–309, 1986

  3. 3.

    Greipp PR, Katzmann JA, O'Fallon WM, Kyle RA: Value of β2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 72:219–223, 1988

  4. 4.

    Durie BGM, Stock-Novack D, Salmon SE, Finley P, Backord J, Crowley J, Coltman CA: Prognostic value of pretreatment serum β2-microglobulin in myeloma: A Southwest Oncology Group study Blood 75:823–830, 1990

  5. 5.

    Scarffe JH, Anderson H, Palmer MK, Crowther D: Prognostic significance of pretreatment serum β2-microglobulin levels in multiple myeloma. Eur J Cancer Clin Oncol 19:1361–1364, 1983

  6. 6.

    Alexanian R, Barlogie B, Fritsche H: β2-Microglobulin in multiple myeloma. Am J Hematol 20:345–351, 1985

  7. 7.

    Bataille R, Vincent C, Revillard JP, Sany J: Serum β2-microglobulin binding activity in monoclonal gammopathy: Correlative study and clinical significance. Eur J Cancer Clin Oncol 19:1075–1080, 1983

  8. 8.

    Cuzik J, De Stavola BL, Cooper EH, Chapman C, Maclennan CM: Long-term prognostic value of serum β2-microglobulin in myelomatosis. Br J Haematol 75:506–510, 1990

  9. 9.

    Zhang XG, Klein B, Bataille R: Interleukin-6 is a potent myeloma-cell Growth factor in patients with aggressive multiple myeloma. Blood 74:11–13, 1989

  10. 10.

    Barlogie B, Epstein J, Selvanayagam P, Alexanian R: Plasma cell myeloma—New biological insights and advances in therapy. Blood 73:865–879, 1989

  11. 11.

    Lauria F, Foa R, Cavo M, Gobbi M, Raspadori D, Guibellino MC, Tazzari PL, Tura S: Membrane phenotype and functional behaviour of T Lymphocytes in multiple myeloma: Correlation with clinical stages of the disease. Clin Exp Immunol 56:653–658, 1984

  12. 12.

    Bergmann L, Mitrou PS, Weber KC, Kelker W: Imbalances of T-cell subsets in monoclonal gammopathies. Cancer Immunol Immunother 17:112–116, 1984

  13. 13.

    Platsoucas CD, Hansen HJ, Redman JR, Bereson S, Lee BJ, Clarkson BD: T-cell imbalances in patients with multiple myeloma: An analysis by monoclonal antibodies. J Clin Immunol 3:277–284, 1983

  14. 14.

    Hoover RG, Lynch RG: Lymphocyte surface membrane immunoglobulin in myeloma II. T cells with IgA-Fc receptors are markedly increased in mice with IgA plasmacytomas. J Immunol 125:1280–1285, 1980

  15. 15.

    Müller S, Hoover RG: T cells with Fc receptors in myeloma: Suppression of growth and secretion of MOPC-315 by T cells J Immunol 134:644–647, 1985

  16. 16.

    Hoover RG, Hickman S, Gebel HM, Rebbe N, Lynch RG: Expansion of Fc receptor-bearing T lymphocytes in patients with Immunogloublin G and Immunoglobulin A myeloma. J Clin Invest 67:308–315, 1981

  17. 17.

    Teillaud JL, Brunati S, Elmalek M, Astier A, Nicaise E, Moncuit J, Mathiot C, Job-Deslandre C, Fridman WH: Involvement of FcR+ T cells and of IgG-BF in the control of myeloma cells. Mol Immunol 27:1209–1217, 1990

  18. 18.

    Fridman WH, Bonnerot C, Daëron M, Amigorena S, Teillaud JL, Sautès C: Structural bases of FcγR functions. Immunol Rev 125:49–76, 1992

  19. 19.

    Lynch A, Tartour E, Teillaud JL, Asselain B, Fridman WH, Sautès C: Increased levels of soluble low affinity Fcγ receptor (IgG-binding factor) in the sera of tumour-bearing mice. Clin Exp Immunol 87:208–214, 1992

  20. 20.

    Teillaud JL, Amigorena S, Moncuit J, Sautes C, Fridman WH: Immunoglobulin-binding factors (IgG-BF) inhibit IgG secretion by, as well as proliferation of hybridoma B cells. Immunol Lett 16:139–144, 1987

  21. 21.

    Ravetch JV, Kinet JP: Fc receptors. Annu Rev Immunol 9:457–492, 1991

  22. 22.

    Fridman WH, Mathiot C, Moncuit J, Teillaud JL: Fc receptors, immunoglobulin-binding factors and B chronic lymphocytic leukemia. Nouv Rev Franc Hematol 30:311–315, 1988

  23. 23.

    Selvaraj P, Rosse F, Silber R, Springer TA: The major Fc receptors in blood has a phosphatidylinositol anchor and is deficient in paroxismal nocturnal haemoglobinuria. Nature 333:565–567, 1988

  24. 24.

    Huizinga TWJ, de Haas M, Kleijer M, Nuijens JH, Roos D, von dem Borne AEG Kr: Soluble Fcγ receptor III in human plasma originates from neutrophils. J Clin Invest 86:416–423, 1990

  25. 25.

    Khayat D, Yoon S, Scligliano E, Soubrane C, Weil M, Unkeless RG: Soluble circulating FcγR in human serum, a new ELISA assay for specific and quantitative detection. J Immunol Methods 100:235–241, 1987

  26. 26.

    Fleit HB, Wright SD, Unkeless JC: Human neutrophil Fc receptor distribution and structure. Proc Natl Acad Sci USA 79:3275–3279, 1982

  27. 27.

    Thibaut E, Amigorena S, Moncuit J, Fridman WH, Teillaud JL: Software for the quantitative evaluation ofin vitro monoclonal antibody production from ELISA data. J Immunol Methods 104:15–24, 1987

  28. 28.

    Huizinga TWJ, Kuijpers RWAM, Kleijer M, Schulpen TWJ, Cuypers HTM, Roos D, von dem Borne AEG Kr: Maternal genomic FcγRIII deficiency leading to isoimmune neutropenia. Blood 76:1927–1932, 1990

  29. 29.

    Ornellas EP, Lebeau MM, Venkataraman M, Thomas W, Amin BR, Westbrook CA, Westerman MP: Coexistent double gammopathy, myeloproliferative disorder and malignant lymphoma. Am J Clin Pathol 93:132–137, 1990

  30. 30.

    Stewart AK, Freedman J, Garvey MB: Acute leukemia evolving from multiple myeloma and co-expressing myeloid and plasma cell antigens. Am J Hematol 34:210–214, 1990

  31. 31.

    Aurojo-Jorje T, Rivera MT, El Bouhdidi A, Daëron M, Carlier Y: FcγRIII-dependentin vivo control of trypanosoma cruzi infection in mice (submitted for publication)

  32. 32.

    Laporte JP, Mathiot C, Isnard F, Elmalek M, Gorin NG, Najman A, Fridman WH, Teillaud JL: Induction of soluble FcγRIII (sCD16) in the serum of refractory multiple myeloma patients by intravenous intravenous injections of polyclonal human IgG (submitted for publication)

Download references

Author information

Correspondence to W. H. Fridman.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Mathiot, C., Teillaud, J.-., Elmalek, M. et al. Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma. J Clin Immunol 13, 41–48 (1993).

Download citation

Key words

  • IgG-specific Fc receptor type III (FcγRIII)
  • CD16
  • prognostic markers
  • myeloma